Rifabutin and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Rifabutin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Rifabutin can make your buprenorphine work less well. Rifabutin (Mycobutin) speeds up an enzyme in your liver (called CYP3A4) that breaks down buprenorphine. When buprenorphine is cleared out faster, its blood level drops. That means you may not get enough pain relief, or if you take it for opioid dependence, you could feel withdrawal symptoms like nausea, sweating, chills, aching, or a racing heart.
The good news is this is very manageable. Please don't stop or change either medicine on your own. Let your doctor or pharmacist know you take both, so they can adjust your buprenorphine dose and keep a closer eye on you while you're on rifabutin.
Effect: Rifabutin, a CYP3A4 inducer, increases CYP3A4-mediated metabolism of buprenorphine, decreasing buprenorphine plasma concentrations (reduced exposure/AUC) and efficacy. This can precipitate opioid withdrawal. Neither agent's active effect depends on prodrug activation here, so induction reduces buprenorphine effect.
- Direction: reduced buprenorphine effect (loss of analgesia/maintenance efficacy, withdrawal risk)
- Onset: unspecified; enzyme induction typically develops over days
- Evidence: probable; severity major
Management: If rifabutin is needed, titrate buprenorphine upward to stable effect and monitor for withdrawal. On rifabutin discontinuation, consider a buprenorphine dose reduction and monitor for respiratory depression. For long-acting/subQ formulations, verify adequate levels or use a formulation allowing precise titration.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inducer can lower buprenorphine plasma concentrations, potentially triggering opioid withdrawal symptoms. When a CYP3A4 inducer must be given to a patient already on buprenorphine, one option is to raise the buprenorphine dose until stable drug effects are reached while watching for signs of withdrawal. Conversely, if a CYP3A4 inducer is stopped in a patient receiving buprenorphine, a reduction in the buprenorphine dose should be considered along with monitoring for respiratory depression2. Should the dose prove impossible to adjust once the CYP3A4 inducer is gone, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients being converted from transmucosal buprenorphine taken alongside CYP3A4 inducers, confirm through monitoring that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient. When a patient already receiving subQ buprenorphine needs a CYP3A4 inducer, monitor for withdrawal. If the buprenorphine dose is insufficient while the concomitant drug is present and that drug cannot be decreased or stopped, modify the buprenorphine dose. When the available doses are unable to deliver the target dose, use a buprenorphine formulation that permits more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what your team typically does:
- If rifabutin is started, your buprenorphine dose may need to be increased and individualized until your symptoms are stable, while your team watches for withdrawal signs.
- If rifabutin is later stopped, your buprenorphine dose may be lowered, and your team may monitor you more closely for oversedation or slowed breathing.
- With long-acting or injectable buprenorphine, your team may check that your dose stays adequate, or switch to a form that allows finer dose adjustments.
Tell your pharmacist or prescriber you take both, and report any withdrawal symptoms (sweating, nausea, aches, restlessness).
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in patients receiving subQ buprenorphine has not been evaluated; nevertheless, such interactions have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Rifabutin and Buprenorphine together?
Rifabutin can lower buprenorphine levels and trigger withdrawal or weaker effect; don't change anything yourself, but tell your prescriber or pharmacist so they can adjust your dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Rifabutin and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Rifabutin and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what your team typically does: If rifabutin is started, your buprenorphine dose may need to be increased and individualized until your symptoms are stable, while your team watches for withdrawal signs. If rifabutin is later stopped, your buprenorphine dose may be lowered, and your team may monitor you more… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Rifabutin or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Rifabutin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist